GLP-1 for PCOS

Polycystic ovary syndrome affects somewhere between 8 and 13% of women of reproductive age, which makes it one of the most common endocrine disorders there is. The defining features are excess androgen, disrupted ovulation, and frequently a polycystic appearance on ultrasound. What patients notice is different: periods that are irregular or absent, hair growing where they do not want it, acne, and difficulty getting pregnant.

Underneath most of it sits insulin resistance, and it is present in the majority of women with PCOS whatever they weigh. Carrying extra weight makes that resistance worse, which worsens both the metabolic and the reproductive side of the condition — a loop that lifestyle change alone often cannot break.

No GLP-1 drug is approved for PCOS. Every use of one here is off-label, and it generally comes up when PCOS sits alongside overweight or obesity and the first-line options — lifestyle change and metformin — have not been enough. The evidence has grown considerably since 2022, and now includes several randomized trials and meta-analyses rather than case series.

The broadest recent evidence was assembled to inform the international PCOS guideline: a 2024 systematic review and meta-analysis in Obesity Reviews found that anti-obesity drugs, this class among them, significantly lowered BMI, waist circumference and fasting insulin against placebo in women with PCOS. [1]

A 2024 meta-analysis restricted to randomized trials in women with PCOS and obesity found the same direction on weight, and added hormonal outcomes: free androgen levels fell and menstrual regularity improved, with a safety profile the authors considered acceptable. [2]

Pooling multiple randomized trials, a 2024 review in Archives of Physiological Biochemistry reported reductions in BMI, fasting glucose, fasting insulin and HOMA-IR — the last being the standard index of insulin resistance, and arguably the most relevant of the four given what drives this condition. [3]

The single strongest study design here is a phase 3 placebo-controlled trial in Fertility & Sterility. Among women who had both obesity and PCOS, a daily 3 mg dose of liraglutide beat placebo on weight, and on fasting insulin, HOMA-IR and total testosterone as well. [4]

Adding liraglutide on top of metformin — rather than replacing it — improved both gonadal and metabolic measures beyond what metformin achieved alone in overweight women with PCOS, which suggests the two are additive rather than interchangeable. [5]

Durability is the question most trials cannot answer, and one observational study ran two years to try. Weight lost on semaglutide was largely held after the semaglutide stopped, in women who stayed on metformin — pointing to a metabolic shift that outlasted the drug that produced it. [6]

A 2023 narrative review set out the mechanism that ties this together: these drugs cut hepatic glucose output, improve beta-cell function and lower circulating insulin, and hyperinsulinemia is itself a driver of androgen overproduction in PCOS. On that reading the effect on androgens is downstream of the insulin effect rather than separate from it. [7]

Compared head to head with metformin in a 2019 meta-analysis, GLP-1 receptor agonists matched or beat it on BMI and insulin resistance, taking off more weight while metformin held an edge on glucose lowering in some analyses. That split is the practical argument for individualizing the choice around which burden dominates for a given patient. [8]

Anyone whose PCOS comes with a BMI at or above 27, where lifestyle change alone — or metformin — has left metabolic or hormonal control short of where it needs to be.

Women with PCOS who have documented insulin resistance or prediabetes, where an insulin-sensitizing drug that also produces weight loss addresses the metabolic and reproductive drivers at the same time.

Women who are not pregnant, are not trying to conceive in the near term, and are using reliable contraception. These drugs have to stop before conception, and that is a condition of starting rather than a detail to sort out later.

Because the use is off-label, the clinical rationale belongs in the chart, the evidence should be discussed honestly rather than oversold, and the decision made jointly. Some payers will only authorize against the obesity or prediabetes diagnosis, not against PCOS itself.

Nothing in this class is approved for PCOS. A patient starting one should understand they are taking a drug licensed for obesity or type 2 diabetes and applying it to a related condition on evidence that is growing but not settled.

Metformin remains the established first-line drug for the metabolic side of PCOS and costs a fraction as much. GLP-1s generally enter the picture when metformin is not enough or not tolerated, or when the weight loss itself is the point.

These drugs are contraindicated in pregnancy and should stop at least two months before any attempt to conceive. That matters more here than elsewhere, because weight loss can restore ovulation in women who had assumed they were not fertile.

Evidence on actual fertility outcomes — IVF success, live births — remains limited. Improvements in cycle regularity and ovulation have been reported, and that is not the same as a fertility treatment. It should not be presented as one.

Gastrointestinal side effects are the most common problem and scale with dose, which is why titration is slow. The rarer serious risks, pancreatitis and gallbladder disease, apply here exactly as they do to anyone else taking these drugs.

Hirsutism and acne may ease somewhat as weight and circulating insulin fall. They should not displace targeted treatment — anti-androgens, combined oral contraceptives — where that is what the symptom actually calls for.